These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8816151)

  • 21. Immunoprotective potential of polysaccharide-tetanus toxoid conjugate in Klebsiella pneumoniae induced lobar pneumonia in rats.
    Chhibber S; Rani M; Vanashree Y
    Indian J Exp Biol; 2005 Jan; 43(1):40-5. PubMed ID: 15691064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants.
    Twumasi PA; Kumah S; Leach A; O'Dempsey TJ; Ceesay SJ; Todd J; Broome CV; Carlone GM; Pais LB; Holder PK
    J Infect Dis; 1995 Mar; 171(3):632-8. PubMed ID: 7876610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study.
    Hatz CF; Bally B; Rohrer S; Steffen R; Kramme S; Siegrist CA; Wacker M; Alaimo C; Fonck VG
    Vaccine; 2015 Aug; 33(36):4594-601. PubMed ID: 26162850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polysaccharide conjugate vaccine protein carriers as a "neglected valency" - Potential and limitations.
    Bröker M; Berti F; Schneider J; Vojtek I
    Vaccine; 2017 Jun; 35(25):3286-3294. PubMed ID: 28487056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
    Cryz SJ; Sadoff JC; Ohman D; Fürer E
    J Lab Clin Med; 1988 Jun; 111(6):701-7. PubMed ID: 3131471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans.
    Cryz SJ; Sadoff JC; Fürer E; Germanier R
    J Infect Dis; 1986 Oct; 154(4):682-8. PubMed ID: 3091708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-idiotype vaccines for immunity to bacterial polysaccharides: induction of functional antibodies to polysaccharide antigens of Pseudomonas aeruginosa.
    Schreiber JR
    Springer Semin Immunopathol; 1993; 15(2-3):235-46. PubMed ID: 7504840
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis.
    Schaad UB; Lang AB; Wedgwood J; Ruedeberg A; Que JU; Fürer E; Cryz SJ
    Lancet; 1991 Nov; 338(8777):1236-7. PubMed ID: 1682645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants.
    Dagan R; Kayhty H; Wuorimaa T; Yaich M; Bailleux F; Zamir O; Eskola J
    Pediatr Infect Dis J; 2004 Feb; 23(2):91-8. PubMed ID: 14872172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.
    da Silva MA; Converso TR; Gonçalves VM; Leite LCC; Tanizaki MM; Barazzone GC
    Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28637805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.
    Cryz SJ; Fürer E; Cross AS; Wegmann A; Germanier R; Sadoff JC
    J Clin Invest; 1987 Jul; 80(1):51-6. PubMed ID: 3110215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease.
    Vernacchio L; Romero-Steiner S; Martinez JE; MacDonald K; Barnard S; Pilishvili T; Carlone GM; Ambrosino DM; Molrine DC
    J Infect Dis; 2000 Mar; 181(3):1162-6. PubMed ID: 10720547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines.
    Daum RS; Hogerman D; Rennels MB; Bewley K; Malinoski F; Rothstein E; Reisinger K; Block S; Keyserling H; Steinhoff M
    J Infect Dis; 1997 Aug; 176(2):445-55. PubMed ID: 9237711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylaxis and therapy of Pseudomonas aeruginosa infection in cystic fibrosis and immunocompromised patients.
    Lang AB; Horn MP; Imboden MA; Zuercher AW
    Vaccine; 2004 Dec; 22 Suppl 1():S44-8. PubMed ID: 15576201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pseudomonas aeruginosa antigens as potential vaccines.
    Stanislavsky ES; Lam JS
    FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity differences of a 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15) based on vaccine dose, route of immunization and mouse strain.
    Caro-Aguilar I; Indrawati L; Kaufhold RM; Gaunt C; Zhang Y; Nawrocki DK; Giovarelli C; Winters MA; Smith WJ; Heinrichs J; Skinner JM
    Vaccine; 2017 Feb; 35(6):865-872. PubMed ID: 28087148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response of recent human immunodeficiency virus seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type b conjugate vaccine.
    Weiss PJ; Wallace MR; Oldfield EC; O'Brien J; Janoff EN
    J Infect Dis; 1995 May; 171(5):1217-22. PubMed ID: 7751696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine.
    Gadzinowski J; Albrecht P; Hasiec B; Konior R; Dziduch J; Witor A; Mellelieu T; Tansey SP; Jones T; Sarkozy D; Emini EA; Gruber WC; Scott DA
    Vaccine; 2011 Apr; 29(16):2947-55. PubMed ID: 21335032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
    Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
    Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.